media Media
Press Releases2020-05-07T14:51:44+00:00

Press Releases

Eosinophilic Esophagitis, a Complex, Chronic Autoimmune Condition, Awaits FDA-Approved Therapies, Potentially Including a Biologic Option, According to Spherix Global Insights

With both steroid-based and advanced therapies poised for FDA approval in the near term, gastroenterologists’ general satisfaction with current eosinophilic esophagitis treatment options is not optimal  EXTON, Pa., October 29, 2020 /PRNewswire/ — Spherix recently surveyed 103 US gastroenterologists and followed up with ten qualitative interviews (including two with industry key opinion leaders) in order to assess the current and future treatment paradigm of eosinophilic esophagitis (EoE) patients. This new Market Dynamix™ service focusing on EoE was introduced after the disease [...]

October 29, 2020|

Genentech’s Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights

Will impressive uptake of Novartis’ Mayzent in the active secondary progressive multiple sclerosis market over the past two years be enough to unseat Ocrevus in the US? EXTON, Pa., October 27, 2020/PRNewswire/ — While the segment of multiple sclerosis (MS) patients with progressive disease remains underserved, numerous recent approvals for relapsing MS (RMS)—including active secondary progressive MS (SPMS)—have enhanced neurologists’ ability to treat active SPMS patients. Data from 764 charts of disease-modifying therapy (DMT)-treated patients with progressive forms of MS [...]

October 27, 2020|

Spherix Global Insights Climbs the Ranks on Two Lists Recognizing Greater Philadelphia’s Fastest Growing Companies

The Philadelphia Business Journal and The Entrepreneurs’ Forum of Greater Philadelphia have recognized Spherix for the second year in a row as one the area’s fastest growing companies  EXTON, Pa., October 22, 2020 ― In their second year of eligibility, Spherix Global Insights, a market intelligence firm focusing on immunology, nephrology, and neurology markets, is proud to be recognized as one of Philadelphia Business Journal’s Soaring 76 and The Entrepreneurs’ Forum’s Philadelphia100® fastest growing companies in the region. “Five [...]

October 22, 2020|

Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights

Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from Pfizer and Bristol Myers Squibb, as well as a potential label expansion for GlaxoSmithKline’s Benlysta for renal manifestations EXTON, Pa., September 30, 2020 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease and few effective treatment options. When it was approved in 2011, GSK’s Benlysta represented the [...]

September 30, 2020|

The Need for Greater Efficacy Drives Increased Switching from Branded TNF Inhibitors to Takeda’s Entyvio, Janssen’s Stelara, and Pfizer’s Xeljanz in US Inflammatory Bowel Disease Market

A newly published report by Spherix Global Insights includes the responses of 216 gastroenterologists and 1,026 audited patient records in the US and reveals the current treatment approach for recently switched ulcerative colitis and Crohn’s disease patients  EXTON, Pa., September 24, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall biologic and JAK therapy prescribing for ulcerative colitis (UC) and Crohn’s disease (CD) patients – [...]

September 24, 2020|

Following a Delayed Launch, Bristol Myers Squibb’s Zeposia has Begun to Successfully Establish Itself as a Low-Burden Option Within the S1P Receptor Modulator Class, According to Spherix Global Insights

Spherix’s new launch tracking service will further monitor details of Zeposia’s uptake over 18 months and benchmark key metrics against historical launches, including Genentech’s Ocrevus and Novartis’ Mayzent  EXTON, Pa., September 16, 2020 /PRNewswire/ — With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, oral DMT class share has increased slightly over the past year, according to the most recent report included in Spherix’s RealTime Dynamix™: Multiple Sclerosis (US) service. The report, which [...]

September 16, 2020|
Go to Top